BRPI0922652A2 - Derivados de quinazolinamida - Google Patents

Derivados de quinazolinamida

Info

Publication number: BRPI0922652A2
Authority: BR; Brazil
Prior art keywords: quinazolinamide; derivatives; quinazolinamide derivatives
Prior art date: 2008-12-09

Application number

BRPI0922652-4A

Other languages

English (en)

Inventor

Hans-Michael Eggenweiler

Christian Sirrenberg

Hans-Peter Buchstaller

Original Assignee

Merck Patent Ges Mit Beschränkter Haftung

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-12-09

Filing date

2009-11-12

Publication date

2015-08-11

2009-11-12 Application filed by Merck Patent Ges Mit Beschränkter Haftung filed Critical Merck Patent Ges Mit Beschränkter Haftung

2015-08-11 Publication of BRPI0922652A2 publication Critical patent/BRPI0922652A2/pt

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Virology (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Immunology (AREA)
Molecular Biology (AREA)
Neurology (AREA)
Pulmonology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Diabetes (AREA)
Heart & Thoracic Surgery (AREA)
Biotechnology (AREA)
Physical Education & Sports Medicine (AREA)
Hematology (AREA)
Cardiology (AREA)
Dermatology (AREA)
Endocrinology (AREA)
Urology & Nephrology (AREA)
Psychiatry (AREA)
Rheumatology (AREA)
Hospice & Palliative Care (AREA)
Transplantation (AREA)
Tropical Medicine & Parasitology (AREA)
Emergency Medicine (AREA)
Obesity (AREA)

BRPI0922652-4A 2008-12-09 2009-11-12 Derivados de quinazolinamida BRPI0922652A2 (pt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
DE102008061214A DE102008061214A1 (de)	2008-12-09	2008-12-09	Chinazolinamidderivate
PCT/EP2009/008061 WO2010066324A1 (de)	2008-12-09	2009-11-12	Chinazolinamidderivate

Publications (1)

Publication Number	Publication Date
BRPI0922652A2 true BRPI0922652A2 (pt)	2015-08-11

Family

ID=41478685

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0922652-4A BRPI0922652A2 (pt)	2008-12-09	2009-11-12	Derivados de quinazolinamida

Country Status (17)

Country	Link
US (1)	US8546565B2 (pt)
EP (1)	EP2356110B1 (pt)
JP (1)	JP5749653B2 (pt)
KR (1)	KR20110098772A (pt)
CN (1)	CN102245596A (pt)
AR (1)	AR074493A1 (pt)
AU (1)	AU2009326602B2 (pt)
BR (1)	BRPI0922652A2 (pt)
CA (1)	CA2745988C (pt)
DE (1)	DE102008061214A1 (pt)
EA (1)	EA201100872A1 (pt)
ES (1)	ES2564815T3 (pt)
IL (1)	IL213424A (pt)
MX (1)	MX2011005986A (pt)
SG (1)	SG171902A1 (pt)
WO (1)	WO2010066324A1 (pt)
ZA (1)	ZA201105050B (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE102009054302A1 (de) *	2009-11-23	2011-05-26	Merck Patent Gmbh	Chinazolinderivate
DE102010046837A1 (de) *	2010-09-29	2012-03-29	Merck Patent Gmbh	Phenylchinazolinderivate
US9309236B2 (en)	2011-10-05	2016-04-12	The Board Of Trustees Of The Leland Stanford Junior University	PI-kinase inhibitors with broad spectrum anti-infective activity
US9926309B2 (en)	2011-10-05	2018-03-27	The Board Of Trustees Of The Leland Stanford Junior University	Pi-kinase inhibitors with anti-infective activity
AU2013226013B2 (en) *	2012-02-29	2016-08-11	Baruch S. Blumberg Institute	Inhibitors of Hepatitis B Virus Covalently Closed Circular DNA Formation and Their Method of Use
EP3253390B1 (en)	2015-02-06	2022-04-13	Merck Sharp & Dohme Corp.	Aminoquinazoline compounds as a2a antagonist
EP3419980B1 (en)	2016-02-26	2025-01-01	The Board of Trustees of the Leland Stanford Junior University	Pi-kinase inhibitors with anti-infective activity
EP3941909A4 (en)	2019-03-21	2023-01-25	The Board Of Trustees Of The Leland Stanford Junior University	Pi4-kinase inhibitors and methods of using the same
CN115666568A (zh) *	2019-11-15	2023-01-31	佐治亚州立大学研究基金会	小分子聚合酶抑制剂
TW202246232A (zh)	2021-02-19	2022-12-01	英商蘇多生物科學有限公司	Ｔｙｋ２抑制劑及其用途
WO2022175747A1 (en)	2021-02-19	2022-08-25	Sudo Biosciences Limited	Tyk2 inhibitors and uses thereof

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5968921A (en)	1997-10-24	1999-10-19	Orgegon Health Sciences University	Compositions and methods for promoting nerve regeneration
AU3378599A (en)	1998-04-03	1999-10-25	University Of Pittsburgh	Benzoquinoid ansamycins for the treatment of cardiac arrest and stroke
AU776652B2 (en)	1999-03-12	2004-09-16	United States Of America, Represented By The Secretary, Department Of Health And Human Services, The	Method of inhibiting a chaperone protein
AU2001247759A1 (en)	2000-03-24	2001-10-08	Duke University	Characterization of grp94-ligand interactions and purification, screening, and therapeutic methods relating thereto
AU2001271567A1 (en)	2000-06-29	2002-01-14	Trustees Of Boston University	Use of geldanamycin and related compounds for prophylaxis or treatment of fibrogenic disorders
EP1322325A4 (en)	2000-07-20	2004-09-15	Merck & Co Inc	INHIBITION OF PROCESSING AND REPLICATION OF HEPATITIS C VIRUS
US6946456B2 (en)	2000-07-28	2005-09-20	Sloan-Kettering Institute For Cancer Research	Methods for treating cell proliferative disorders and viral infections
KR20040007497A (ko)	2001-04-16	2004-01-24	에자이 가부시키가이샤	신규 1ｈ-인다졸 화합물
EP1450784A4 (en)	2001-11-09	2005-02-09	Conforma Therapeutics Corp	HSP90-INHIBITABLE ZEARALANOL COMPOUNDS AND METHOD FOR THEIR PREPARATION AND USE
US20090039811A1 (en)	2004-07-27	2009-02-12	Patrick Chene	Inhibitors of HSP90
KR20070085677A (ko) *	2004-11-02	2007-08-27	콘포마 세러퓨틱스 코포레이션	만성 림프성 백혈병의 치료 방법 및 치료 조성물
CA2604942A1 (en) *	2005-04-14	2006-10-26	Novartis Vaccines And Diagnostics, Inc.	2-amino-quinaz0lin-5-ones
DE102005022977A1 (de)	2005-05-19	2006-12-07	Merck Patent Gmbh	Phenylchinazolinderivate
DE102005037733A1 (de) *	2005-08-10	2007-02-15	Merck Patent Gmbh	Adeninderivate
CL2007002994A1 (es) *	2006-10-19	2008-02-08	Wyeth Corp	Compuestos derivados heterociclicos que contienen sulfamoilo, inhibidores de hsp90; composicion farmaceutica; y uso para el tratamiento del cancer, tal como cancer de mama, de colon y prostata, entre otros.
KR20090104920A (ko) *	2007-02-01	2009-10-06	아스트라제네카 아베	Ｈｓｐ90 억제제로서 5,6,7,8-테트라히드로프테리딘 유도체
GB2449293A (en) *	2007-05-17	2008-11-19	Evotec	Compounds having Hsp90 inhibitory activity
DE102007032739A1 (de)	2007-07-13	2009-01-15	Merck Patent Gmbh	Chinazolinamidderivate

2008
- 2008-12-09 DE DE102008061214A patent/DE102008061214A1/de not_active Withdrawn
2009
- 2009-11-12 EP EP09751824.5A patent/EP2356110B1/de not_active Not-in-force
- 2009-11-12 US US13/133,495 patent/US8546565B2/en not_active Expired - Fee Related
- 2009-11-12 JP JP2011539912A patent/JP5749653B2/ja not_active Expired - Fee Related
- 2009-11-12 SG SG2011039997A patent/SG171902A1/en unknown
- 2009-11-12 ES ES09751824.5T patent/ES2564815T3/es active Active
- 2009-11-12 BR BRPI0922652-4A patent/BRPI0922652A2/pt not_active IP Right Cessation
- 2009-11-12 EA EA201100872A patent/EA201100872A1/ru unknown
- 2009-11-12 AU AU2009326602A patent/AU2009326602B2/en not_active Ceased
- 2009-11-12 CA CA2745988A patent/CA2745988C/en not_active Expired - Fee Related
- 2009-11-12 KR KR1020117015247A patent/KR20110098772A/ko not_active Withdrawn
- 2009-11-12 MX MX2011005986A patent/MX2011005986A/es active IP Right Grant
- 2009-11-12 WO PCT/EP2009/008061 patent/WO2010066324A1/de not_active Ceased
- 2009-11-12 CN CN2009801492388A patent/CN102245596A/zh active Pending
- 2009-12-07 AR ARP090104724A patent/AR074493A1/es unknown
2011
- 2011-06-06 IL IL213424A patent/IL213424A/en active IP Right Grant
- 2011-07-08 ZA ZA2011/05050A patent/ZA201105050B/en unknown

Also Published As

Publication number	Publication date
AU2009326602A1 (en)	2011-07-28
US20110245225A1 (en)	2011-10-06
JP2012511520A (ja)	2012-05-24
US8546565B2 (en)	2013-10-01
ES2564815T3 (es)	2016-03-29
EP2356110B1 (de)	2016-01-06
MX2011005986A (es)	2011-06-27
CN102245596A (zh)	2011-11-16
CA2745988C (en)	2017-02-28
SG171902A1 (en)	2011-07-28
WO2010066324A1 (de)	2010-06-17
JP5749653B2 (ja)	2015-07-15
DE102008061214A1 (de)	2010-06-10
IL213424A (en)	2014-03-31
ZA201105050B (en)	2012-03-28
EP2356110A1 (de)	2011-08-17
IL213424A0 (en)	2011-07-31
EA201100872A1 (ru)	2012-01-30
AU2009326602B2 (en)	2015-12-17
AR074493A1 (es)	2011-01-19
CA2745988A1 (en)	2010-06-17
KR20110098772A (ko)	2011-09-01

Publication	Publication Date	Title
DK2308877T3 (da)	2014-04-22	Imidazopyridin-2-on-derivater
BRPI0915064A2 (pt)	2015-10-27	derivados de qunoxalinadiona
EP2376493A4 (en)	2012-05-30	DIHYDROPYRIMIDOPYRIMIDINDERIVAT
EP2380877A4 (en)	2012-06-27	PYRIDINE-3-CARBONSÄUREAMIDDERIVAT
BRPI0813707A2 (pt)	2014-12-30	Derivados de pirimidinil-piridazinona
BRPI0820112A2 (pt)	2015-05-05	Derivados de isoxazol-piridina
BRPI0809992A2 (pt)	2014-10-14	Derivados de pirrolopirimidina
BRPI0913832A2 (pt)	2015-10-20	derivados de pirrolopiridinilpirimidin-2-ilamina
BRPI0820113A2 (pt)	2015-05-05	Derivados de isoxazolo-piridazina
BRPI0812155A2 (pt)	2019-09-24	derivados de espiroindolinona
BRPI1013246A2 (pt)	2016-04-05	derivados de benzofuralina
BR112012002828A2 (pt)	2015-10-13	derivados de 5-fluorpirimidinona
BRPI0817935A2 (pt)	2015-04-07	Derivados de biarila
BRPI0921327A2 (pt)	2015-08-25	Combinação de herbicida-protetor
DK2209786T3 (da)	2013-06-03	Pyrimidinsubstituerede purinderivater
DK2340021T3 (da)	2012-12-10	Substituerede pyrrolidin-2-carboxamider
BRPI0814236A2 (pt)	2015-01-06	Derivados de quinazolinamida
BRPI0813836A2 (pt)	2015-01-06	Derivados pirazólicos
BRPI0812518A2 (pt)	2015-03-31	Derivados de indazolamida
EP2336132A4 (en)	2012-03-21	MORPHOLINPURINDERIVAT
BRPI0820649A2 (pt)	2015-06-16	Derivados de isoxazalo-pirazina
BRPI1013844A2 (pt)	2016-04-12	derivados de piridina-isoxazol
DK2275414T3 (da)	2015-06-22	Cyclopentylacrylamidderivat
DK2152370T3 (da)	2011-08-15	Aryletherpyridazinonderivater
BRPI0913234A2 (pt)	2016-01-19	derivados de tiazolilpiperidina

Legal Events

Date	Code	Title	Description
2015-12-08	B08F	Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]	Free format text: REFERENTE AS 5A E 6A ANUIDADES.
2016-04-05	B08K	Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]	Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2344 DE 08-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.